CCND1 amplification
|
Melanoma
|
CCND1 amplification
|
Melanoma
|
sorafenib Sensitive: B - Late Trials
|
sorafenib Sensitive: B - Late Trials
|
CCND1 amplification
|
Estrogen Receptor Positive Breast Cancer
|
CCND1 amplification
|
Estrogen Receptor Positive Breast Cancer
|
palbociclib Resistant: C3 – Early Trials
|
palbociclib Resistant: C3 – Early Trials
|
CCND1 amplification
|
Solid Tumor
|
CCND1 amplification
|
Solid Tumor
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
CCND1 amplification
|
Breast Cancer
|
CCND1 amplification
|
Breast Cancer
|
Aromatase inhibitor Resistant: C3 – Early Trials
|
Aromatase inhibitor Resistant: C3 – Early Trials
|
CCND1 amplification
|
Melanoma
|
CCND1 amplification
|
Melanoma
|
ribociclib Sensitive: C3 – Early Trials
|
ribociclib Sensitive: C3 – Early Trials
|
CCND1 amplification
|
Lung Non-Small Cell Squamous Cancer
|
CCND1 amplification
|
Lung Non-Small Cell Squamous Cancer
|
palbociclib Sensitive: C3 – Early Trials
|
palbociclib Sensitive: C3 – Early Trials
|
CCND1 amplification
|
Melanoma
|
CCND1 amplification
|
Melanoma
|
toripalimab Resistant: C3 – Early Trials
|
toripalimab Resistant: C3 – Early Trials
|
CCND1 amplification
|
Head and Neck Cancer
|
CCND1 amplification
|
Head and Neck Cancer
|
cetuximab + palbociclib Sensitive: C3 – Early Trials
|
cetuximab + palbociclib Sensitive: C3 – Early Trials
|
CCND1 amplification
|
Breast Cancer
|
CCND1 amplification
|
Breast Cancer
|
lapatinib Sensitive: D – Preclinical
|
lapatinib Sensitive: D – Preclinical
|